JP6144201B2 - 複素環化合物およびグリコーゲンシンターゼキナーゼ−３阻害薬としてのそれの使用 - Google Patents
複素環化合物およびグリコーゲンシンターゼキナーゼ−３阻害薬としてのそれの使用 Download PDFInfo
- Publication number
- JP6144201B2 JP6144201B2 JP2013546715A JP2013546715A JP6144201B2 JP 6144201 B2 JP6144201 B2 JP 6144201B2 JP 2013546715 A JP2013546715 A JP 2013546715A JP 2013546715 A JP2013546715 A JP 2013546715A JP 6144201 B2 JP6144201 B2 JP 6144201B2
- Authority
- JP
- Japan
- Prior art keywords
- urea
- quinolin
- pyridin
- pyran
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 *C1=C(*C(N(*)C(*I=**=*)=N*)=O)**N=C1C(N*)=O Chemical compound *C1=C(*C(N(*)C(*I=**=*)=N*)=O)**N=C1C(N*)=O 0.000 description 20
- GESLXCHQOQGEAN-SHMLVVSMSA-N CC1(CCOCC1)/C(/C)=N/C(/NC(NC(C(CN)=C)=C)O)=C\C Chemical compound CC1(CCOCC1)/C(/C)=N/C(/NC(NC(C(CN)=C)=C)O)=C\C GESLXCHQOQGEAN-SHMLVVSMSA-N 0.000 description 1
- OHHJJQZGSOYSCF-UHFFFAOYSA-N Cc(cc1Cl)cc2c1nccc2NC(Nc1nc(C2CCOCC2)ccc1)=O Chemical compound Cc(cc1Cl)cc2c1nccc2NC(Nc1nc(C2CCOCC2)ccc1)=O OHHJJQZGSOYSCF-UHFFFAOYSA-N 0.000 description 1
- URPIWIXRYAYPQV-UHFFFAOYSA-N Cc1ccc(C2CCOCC2)nc1NC(Nc1ccnc2c1cccc2Cl)=O Chemical compound Cc1ccc(C2CCOCC2)nc1NC(Nc1ccnc2c1cccc2Cl)=O URPIWIXRYAYPQV-UHFFFAOYSA-N 0.000 description 1
- FBWWNLBZZFVRQY-UHFFFAOYSA-N O=C(Nc1ccnc2c1cccc2C(F)(F)F)Nc1cccc(C(F)(F)F)n1 Chemical compound O=C(Nc1ccnc2c1cccc2C(F)(F)F)Nc1cccc(C(F)(F)F)n1 FBWWNLBZZFVRQY-UHFFFAOYSA-N 0.000 description 1
- GWCWCWXMAZCRIV-UHFFFAOYSA-N O=C(Nc1ccnc2c1cccc2F)Nc1nc(C2=COCCC2)ccc1 Chemical compound O=C(Nc1ccnc2c1cccc2F)Nc1nc(C2=COCCC2)ccc1 GWCWCWXMAZCRIV-UHFFFAOYSA-N 0.000 description 1
- VBISSAFCYVKVAC-UHFFFAOYSA-N O=C(Nc1ccnc2c1cccc2F)Nc1nc(C2CCN(CC(F)F)CC2)ccc1 Chemical compound O=C(Nc1ccnc2c1cccc2F)Nc1nc(C2CCN(CC(F)F)CC2)ccc1 VBISSAFCYVKVAC-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201061428478P | 2010-12-30 | 2010-12-30 | |
| US61/428,478 | 2010-12-30 | ||
| US201161521868P | 2011-08-10 | 2011-08-10 | |
| US61/521,868 | 2011-08-10 | ||
| PCT/EP2011/074272 WO2012089828A2 (en) | 2010-12-30 | 2011-12-30 | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017011851A Division JP2017122089A (ja) | 2010-12-30 | 2017-01-26 | 複素環化合物およびグリコーゲンシンターゼキナーゼ−３阻害薬としてのそれの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014501269A JP2014501269A (ja) | 2014-01-20 |
| JP2014501269A5 JP2014501269A5 (https=) | 2015-02-19 |
| JP6144201B2 true JP6144201B2 (ja) | 2017-06-07 |
Family
ID=45524498
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013546715A Expired - Fee Related JP6144201B2 (ja) | 2010-12-30 | 2011-12-30 | 複素環化合物およびグリコーゲンシンターゼキナーゼ−３阻害薬としてのそれの使用 |
| JP2017011851A Pending JP2017122089A (ja) | 2010-12-30 | 2017-01-26 | 複素環化合物およびグリコーゲンシンターゼキナーゼ−３阻害薬としてのそれの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017011851A Pending JP2017122089A (ja) | 2010-12-30 | 2017-01-26 | 複素環化合物およびグリコーゲンシンターゼキナーゼ−３阻害薬としてのそれの使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9090592B2 (https=) |
| EP (2) | EP2658854B1 (https=) |
| JP (2) | JP6144201B2 (https=) |
| KR (1) | KR101860297B1 (https=) |
| CN (1) | CN103476766B (https=) |
| AU (1) | AU2011351375B2 (https=) |
| BR (1) | BR112013016928A2 (https=) |
| CA (1) | CA2821863A1 (https=) |
| IL (1) | IL226676A (https=) |
| MX (1) | MX336346B (https=) |
| NZ (1) | NZ611314A (https=) |
| RU (1) | RU2623427C2 (https=) |
| SG (2) | SG10201406098UA (https=) |
| WO (1) | WO2012089828A2 (https=) |
| ZA (1) | ZA201304756B (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017122089A (ja) * | 2010-12-30 | 2017-07-13 | アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー | 複素環化合物およびグリコーゲンシンターゼキナーゼ−３阻害薬としてのそれの使用 |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007312165A1 (en) * | 2006-10-21 | 2008-04-24 | Abbott Gmbh & Co. Kg | Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors |
| CA2810954A1 (en) | 2010-09-27 | 2012-04-05 | Abbott Gmbh & Co. Kg | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
| JP6534098B2 (ja) * | 2014-09-12 | 2019-06-26 | 国立大学法人 鹿児島大学 | 成人ｔ細胞白血病治療薬 |
| WO2018165385A1 (en) * | 2017-03-08 | 2018-09-13 | Cornell University | Inhibitors of malt1 and uses thereof |
| RU2739489C2 (ru) * | 2018-03-06 | 2020-12-24 | Закрытое Акционерное Общество "Биокад" | Новые гетероциклические соединения как ингибиторы CDK8/19 |
| CN112823006B (zh) * | 2018-10-17 | 2024-09-17 | 杜克大学 | 用作神经保护剂的醌还原酶2抑制剂 |
| EP3920885A1 (en) | 2019-02-08 | 2021-12-15 | Frequency Therapeutics, Inc. | Valproic acid compounds and wnt agonists for treating ear disorders |
| HRP20251479T1 (hr) * | 2019-11-01 | 2026-01-02 | Syngenta Crop Protection Ag | Pesticidno aktivni kondenzirani biciklički heteroaromatski spojevi |
| WO2021257863A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Pyrrolotriazine compounds as jak2 v617f inhibitors |
| WO2021257857A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Naphthyridinone compounds as jak2 v617f inhibitors |
| SMT202500271T1 (it) | 2020-07-02 | 2025-09-12 | Incyte Corp | Composti di urea triciclici come inibitori di v617f di jak2 |
| US11767323B2 (en) | 2020-07-02 | 2023-09-26 | Incyte Corporation | Tricyclic pyridone compounds as JAK2 V617F inhibitors |
| US11661422B2 (en) | 2020-08-27 | 2023-05-30 | Incyte Corporation | Tricyclic urea compounds as JAK2 V617F inhibitors |
| WO2022140231A1 (en) | 2020-12-21 | 2022-06-30 | Incyte Corporation | Deazaguaine compounds as jak2 v617f inhibitors |
| AR125273A1 (es) | 2021-02-25 | 2023-07-05 | Incyte Corp | Lactamas espirocíclicas como inhibidores de jak2 v617f |
| CN119173514A (zh) | 2022-03-17 | 2024-12-20 | 因赛特公司 | 作为jak2 v617f抑制剂的三环脲化合物 |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY115155A (en) | 1993-09-09 | 2003-04-30 | Upjohn Co | Substituted oxazine and thiazine oxazolidinone antimicrobials. |
| PT1019385E (pt) | 1995-09-15 | 2004-06-30 | Upjohn Co | N-oxidos de aminoaril-oxazolidinona |
| AUPP003197A0 (en) * | 1997-09-03 | 1997-11-20 | Fujisawa Pharmaceutical Co., Ltd. | New heterocyclic compounds |
| US20030220234A1 (en) | 1998-11-02 | 2003-11-27 | Selvaraj Naicker | Deuterated cyclosporine analogs and their use as immunodulating agents |
| KR100581199B1 (ko) | 1998-06-19 | 2006-05-17 | 카이론 코포레이션 | 글리코겐 신타제 키나제 3의 억제제 |
| UA73492C2 (en) * | 1999-01-19 | 2005-08-15 | Aromatic heterocyclic compounds as antiinflammatory agents | |
| GB9918037D0 (en) | 1999-07-30 | 1999-09-29 | Biochemie Gmbh | Organic compounds |
| US6387900B1 (en) | 1999-08-12 | 2002-05-14 | Pharmacia & Upjohn S.P.A. | 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents |
| PY0117895A (es) | 2000-07-31 | 2003-11-03 | Pfizer Prod Inc | Derivados de imidazol |
| IL154016A0 (en) | 2000-08-31 | 2003-07-31 | Pfizer Prod Inc | Pyrazole derivatives and their use as protein kinase inhibitors |
| EP1317450B1 (en) | 2000-09-15 | 2006-11-22 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| EP1392348B1 (en) | 2001-04-30 | 2008-07-09 | AEterna Zentaris GmbH | Treatment of dementia and neurodegenerative diseases with intermediate doses of lhrh antagonists |
| DE10123586A1 (de) | 2001-05-08 | 2002-11-28 | Schering Ag | 3,5-Diamino-1,2,4-triazole als Kinase Inhibitoren |
| EP1256578B1 (en) | 2001-05-11 | 2006-01-11 | Pfizer Products Inc. | Thiazole derivatives and their use as cdk inhibitors |
| SE0102439D0 (sv) | 2001-07-05 | 2001-07-05 | Astrazeneca Ab | New compounds |
| JP5039268B2 (ja) | 2001-10-26 | 2012-10-03 | アベンティス・ファーマスーティカルズ・インコーポレイテツド | ベンゾイミダゾールおよび類縁体および蛋白キナーゼ阻害剤としてのその使用 |
| DE60236322D1 (de) | 2001-12-07 | 2010-06-17 | Vertex Pharma | Verbindungen auf pyrimidin-basis als gsk-3-hemmer |
| SE0104340D0 (sv) | 2001-12-20 | 2001-12-20 | Astrazeneca Ab | New compounds |
| SE0104341D0 (sv) | 2001-12-20 | 2001-12-20 | Astrazeneca Ab | New use |
| EP1458711B1 (en) | 2001-12-21 | 2007-07-18 | AstraZeneca AB | Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer s disease and conditions associated with glycogen synthase kinase-3 |
| TW200301123A (en) | 2001-12-21 | 2003-07-01 | Astrazeneca Uk Ltd | New use |
| SE0200979D0 (sv) | 2002-03-28 | 2002-03-28 | Astrazeneca Ab | New compounds |
| WO2004072029A2 (en) | 2003-02-06 | 2004-08-26 | Vertex Pharmaceuticals Incorporated | Pyrazolopyridazines useful as inhibitors of protein kinases |
| PL2256106T3 (pl) | 2003-07-22 | 2015-08-31 | Astex Therapeutics Ltd | Związki 3,4-pochodne 1h-pirazolu i ich zastosowanie jako kinazy zależne od cyklin (cdk) i modulatory kinazy syntazy glikogenu-3 (gsk-3) |
| AU2004267094A1 (en) | 2003-08-20 | 2005-03-03 | Vertex Pharmaceuticals Incorporated | (4 -amino -1,2, 5-oxadiazol-4-yl) -hetxiroaromatic compounds useful as protein kinase inhibitors |
| JP2007513155A (ja) | 2003-12-04 | 2007-05-24 | スミスクライン ビーチャム コーポレーション | 新規化合物 |
| WO2005061519A1 (en) | 2003-12-19 | 2005-07-07 | Takeda San Diego, Inc. | Kinase inhibitors |
| EP1586318A1 (en) | 2004-04-05 | 2005-10-19 | Neuropharma S.A.U. | Thiadiazolidinones as GSK-3 inhibitors |
| WO2005099353A2 (en) | 2004-04-19 | 2005-10-27 | Symed Labs Limited | A novel process for the preparation of linezolid and related compounds |
| EP1781293A1 (en) | 2004-06-04 | 2007-05-09 | Amphora Discovery Corporation | Quinoline- and isoquinoline-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
| WO2005123672A2 (en) | 2004-06-14 | 2005-12-29 | Takeda San Diego, Inc. | Kinase inhibitors |
| JP2008505167A (ja) | 2004-07-05 | 2008-02-21 | アステックス、セラピューティックス、リミテッド | 医薬組成物 |
| EP1768967B1 (en) | 2004-07-20 | 2009-04-22 | Symed Labs Limited | Novel intermediates for linezolid and related compounds |
| WO2006039164A2 (en) | 2004-09-29 | 2006-04-13 | Amr Technology, Inc. | Novel cyclosporin analogues and their pharmaceutical uses |
| WO2006091737A1 (en) | 2005-02-24 | 2006-08-31 | Kemia, Inc. | Modulators of gsk-3 activity |
| TW200716636A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
| WO2007003525A2 (en) | 2005-06-30 | 2007-01-11 | Janssen Pharmaceutica N.V. | Cyclic anilino-pyridinotriazines as gsk-3 inhibitors |
| EP1749523A1 (en) | 2005-07-29 | 2007-02-07 | Neuropharma, S.A. | GSK-3 inhibitors |
| US7514068B2 (en) | 2005-09-14 | 2009-04-07 | Concert Pharmaceuticals Inc. | Biphenyl-pyrazolecarboxamide compounds |
| AR055669A1 (es) | 2005-10-03 | 2007-08-29 | Astrazeneca Ab | Derivados de 3h - imidazo[4, 5 -b]piridina como inhibidores selectivos de gsk3, metodos e internediarios para su preparacion, composiciones farmaceuticas que los contienen y su uso para la elaboracion de un medicamento para el tratamiento de enfermedades neurodegenerativas y mentales. |
| US20090170847A1 (en) | 2006-01-23 | 2009-07-02 | Seung Chul Lee | Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same |
| JP2009525325A (ja) | 2006-02-02 | 2009-07-09 | アストラゼネカ・アクチエボラーグ | ２−ヒドロキシ−３−［５−（モルホリン−４−イルメチル）ピリジン−２−イル］１ｈ−インドール−５−カルボニトリルの遊離塩基又は塩としての医薬用途 |
| WO2007120102A1 (en) | 2006-04-19 | 2007-10-25 | Astrazeneca Ab | New substituted oxindole derivatives |
| EP1849785A1 (en) | 2006-04-28 | 2007-10-31 | Neuropharma, S.A. | N-(2-Thiazolyl)-amide derivatives as GSK-3 inhibitors |
| US7622495B2 (en) | 2006-10-03 | 2009-11-24 | Neurim Pharmaceuticals (1991) Ltd. | Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents |
| AU2007312165A1 (en) * | 2006-10-21 | 2008-04-24 | Abbott Gmbh & Co. Kg | Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors |
| US8796267B2 (en) | 2006-10-23 | 2014-08-05 | Concert Pharmaceuticals, Inc. | Oxazolidinone derivatives and methods of use |
| NZ577768A (en) | 2006-12-19 | 2012-01-12 | Vertex Pharma | Aminopyrimidines useful as inhibitors of protein kinases |
| CA2673368C (en) | 2006-12-19 | 2014-10-28 | The Board Of Trustees Of The University Of Illinois | 3-benzofuranyl-4-indolyl maleimides as potent gsk3 inhibitors for neurogenerative disorders |
| CA2676944C (en) | 2007-02-15 | 2016-01-19 | F. Hoffmann-La Roche Ag | 2-aminooxazolines as taar1 ligands |
| BRPI0810216A2 (pt) | 2007-04-18 | 2014-10-21 | Astrazeneca Ab | Processo para a preparação de composto, composto, e, método de tratamento de distúrbio bipolar |
| JP2010524972A (ja) | 2007-04-19 | 2010-07-22 | コンサート ファーマシューティカルズ インコーポレイテッド | 重水素化したモルホリニル化合物 |
| EP1992624A1 (en) | 2007-05-16 | 2008-11-19 | Sanofi-Aventis | Heteroarylamide pyrimidone compounds |
| US7531685B2 (en) | 2007-06-01 | 2009-05-12 | Protia, Llc | Deuterium-enriched oxybutynin |
| JP5451602B2 (ja) * | 2007-06-08 | 2014-03-26 | アッヴィ・インコーポレイテッド | キナーゼ阻害薬としての５−ヘテロアリール置換インダゾール類 |
| US20090131485A1 (en) | 2007-09-10 | 2009-05-21 | Concert Pharmaceuticals, Inc. | Deuterated pirfenidone |
| US20090118238A1 (en) | 2007-09-17 | 2009-05-07 | Protia, Llc | Deuterium-enriched alendronate |
| US20090088416A1 (en) | 2007-09-26 | 2009-04-02 | Protia, Llc | Deuterium-enriched lapaquistat |
| US20090082471A1 (en) | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched fingolimod |
| EP2209774A1 (en) | 2007-10-02 | 2010-07-28 | Concert Pharmaceuticals Inc. | Pyrimidinedione derivatives |
| US20090105338A1 (en) | 2007-10-18 | 2009-04-23 | Protia, Llc | Deuterium-enriched gabexate mesylate |
| WO2009051782A1 (en) | 2007-10-18 | 2009-04-23 | Concert Pharmaceuticals Inc. | Deuterated etravirine |
| AU2008317375B2 (en) | 2007-10-26 | 2013-02-28 | Concert Pharmaceuticals, Inc. | Deuterated darunavir |
| JP5756011B2 (ja) * | 2008-04-24 | 2015-07-29 | アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー | グリコーゲン合成酵素キナーゼ３（ｇｓｋ−３）としての１−（７−（ヘキサヒドロピロロ［３，４−ｃ］ピロール−２（１ｈ）−イル）キノリン−４−イル）−３−（ピラジン−２−イル）尿素誘導体とその関連化合物 |
| TW201040191A (en) | 2009-03-27 | 2010-11-16 | Abbott Gmbh & Co Kg | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
| US9090592B2 (en) * | 2010-12-30 | 2015-07-28 | AbbVie Deutschland GmbH & Co. KG | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
-
2011
- 2011-12-29 US US13/339,884 patent/US9090592B2/en not_active Expired - Fee Related
- 2011-12-30 RU RU2013135477A patent/RU2623427C2/ru not_active IP Right Cessation
- 2011-12-30 CA CA2821863A patent/CA2821863A1/en not_active Abandoned
- 2011-12-30 WO PCT/EP2011/074272 patent/WO2012089828A2/en not_active Ceased
- 2011-12-30 SG SG10201406098UA patent/SG10201406098UA/en unknown
- 2011-12-30 BR BR112013016928-1A patent/BR112013016928A2/pt not_active IP Right Cessation
- 2011-12-30 NZ NZ611314A patent/NZ611314A/en not_active IP Right Cessation
- 2011-12-30 SG SG2013050703A patent/SG191789A1/en unknown
- 2011-12-30 MX MX2013007702A patent/MX336346B/es unknown
- 2011-12-30 CN CN201180068418.0A patent/CN103476766B/zh not_active Expired - Fee Related
- 2011-12-30 KR KR1020137020021A patent/KR101860297B1/ko not_active Expired - Fee Related
- 2011-12-30 EP EP11811357.0A patent/EP2658854B1/en not_active Not-in-force
- 2011-12-30 JP JP2013546715A patent/JP6144201B2/ja not_active Expired - Fee Related
- 2011-12-30 AU AU2011351375A patent/AU2011351375B2/en not_active Ceased
- 2011-12-30 EP EP17206645.8A patent/EP3351543A1/en not_active Withdrawn
-
2013
- 2013-05-30 IL IL226676A patent/IL226676A/en active IP Right Grant
- 2013-06-25 ZA ZA2013/04756A patent/ZA201304756B/en unknown
-
2015
- 2015-06-15 US US14/740,048 patent/US9540370B2/en not_active Expired - Fee Related
-
2017
- 2017-01-26 JP JP2017011851A patent/JP2017122089A/ja active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017122089A (ja) * | 2010-12-30 | 2017-07-13 | アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー | 複素環化合物およびグリコーゲンシンターゼキナーゼ−３阻害薬としてのそれの使用 |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2013007702A (es) | 2013-11-20 |
| EP3351543A1 (en) | 2018-07-25 |
| AU2011351375B2 (en) | 2016-08-04 |
| JP2017122089A (ja) | 2017-07-13 |
| US20150274724A1 (en) | 2015-10-01 |
| BR112013016928A2 (pt) | 2020-10-27 |
| RU2013135477A (ru) | 2015-02-10 |
| SG10201406098UA (en) | 2014-11-27 |
| US9090592B2 (en) | 2015-07-28 |
| KR20140003518A (ko) | 2014-01-09 |
| CA2821863A1 (en) | 2012-07-05 |
| KR101860297B1 (ko) | 2018-05-23 |
| MX336346B (es) | 2016-01-15 |
| RU2623427C2 (ru) | 2017-06-26 |
| CN103476766B (zh) | 2016-08-10 |
| WO2012089828A3 (en) | 2012-09-20 |
| EP2658854A2 (en) | 2013-11-06 |
| WO2012089828A2 (en) | 2012-07-05 |
| EP2658854B1 (en) | 2017-12-13 |
| ZA201304756B (en) | 2016-07-27 |
| JP2014501269A (ja) | 2014-01-20 |
| AU2011351375A1 (en) | 2013-06-20 |
| US9540370B2 (en) | 2017-01-10 |
| CN103476766A (zh) | 2013-12-25 |
| IL226676A (en) | 2015-08-31 |
| NZ611314A (en) | 2015-06-26 |
| SG191789A1 (en) | 2013-08-30 |
| US20120172376A1 (en) | 2012-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6144201B2 (ja) | 複素環化合物およびグリコーゲンシンターゼキナーゼ−３阻害薬としてのそれの使用 | |
| JP5784001B2 (ja) | 複素環化合物およびグリコーゲンシンターゼキナーゼ−３阻害薬としてのそれの使用 | |
| TW561154B (en) | Isothiazole derivatives useful as anticancer agents | |
| JP5998142B2 (ja) | 複素環化合物およびグリコーゲンシンターゼキナーゼ−３阻害薬としてのその使用 | |
| JP5406030B2 (ja) | 複素環化合物およびそれらのグリコーゲンシンターゼキナーゼ３阻害薬としての使用 | |
| US12552785B2 (en) | Pyrazolo[1,5-α]pyridine derivative, preparation method therefor, and composition and use thereof | |
| JP5756011B2 (ja) | グリコーゲン合成酵素キナーゼ３（ｇｓｋ−３）としての１−（７−（ヘキサヒドロピロロ［３，４−ｃ］ピロール−２（１ｈ）−イル）キノリン−４−イル）−３−（ピラジン−２−イル）尿素誘導体とその関連化合物 | |
| US20240308980A1 (en) | Heteroaryl amides as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof | |
| US20250026743A1 (en) | Heteroaryl-linked analogs as mglu5 negative allosteric modulators and methods of making and using the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141222 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20141222 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20150917 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20151020 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160118 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160415 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20160927 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170126 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20170127 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20170216 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170411 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170510 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6144201 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |